The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 12, 2019

Filed:

Dec. 17, 2015
Applicants:

Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Shanghai, CN;

Yangtze River Pharmaceutical Group Co., Ltd., Jiangsu, CN;

Inventors:

Sida Shen, Shanghai, CN;

Xiaojing Ni, Shanghai, CN;

Zhiyuan Zhang, Shanghai, CN;

Zheng Yang, Shanghai, CN;

Xiangyu He, Shanghai, CN;

Weiwei Wang, Shanghai, CN;

Fusheng Zhou, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/04 (2006.01); C07D 403/04 (2006.01); A61K 31/5377 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 239/42 (2006.01);
U.S. Cl.
CPC ...
C07D 401/04 (2013.01); A61K 31/5377 (2013.01); C07D 239/42 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/14 (2013.01);
Abstract

Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (1) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.


Find Patent Forward Citations

Loading…